Market Indices
Latest News
 |
| ||
Price Targets
Andrew Lazar from Barclays issued a price target of $15.00 for OTLY on 2026-01-16 15:11:44.The adjusted price target was set to $15.00.At the time of the announcement, OTLY...
January 16, 2026 OTLY 1.06%
from Goldman Sachs issued a price target of $142.00 for BNTX on 2026-01-16 11:49:16.The adjusted price target was set to $142.00.At the time of the announcement, BNTX...
January 16, 2026 BNTX 2.74%
Market Movers
| Top Gainers (%) | |||||||||||||||||||
| TLSA Tiziana Life Sciences Ltd | 1.68
15.86% | ||||||||||||||||||
| TC Token Cat Limited | 10.20
13.33% | ||||||||||||||||||
| AACG ATA Creativity Global | 1.15
12.75% | ||||||||||||||||||
| DBVT DBV Technologies S.A. | 20.78
10.53% | ||||||||||||||||||
| NVO Novo Nordisk A/S | 62.33
9.12% | ||||||||||||||||||
| AIXI Xiao-I Corporation | 0.38
9.00% | ||||||||||||||||||
| IMOS ChipMOS TECHNOLOGIES Inc. | 42.50
7.79% | ||||||||||||||||||
| IVA Inventiva S.A. | 6.54
6.78% | ||||||||||||||||||
Annual/Quarterly Reports Summary
Summit Therapeutics Inc. (SMMT) Quarterly Report: What Does It Reveal About Their Sector Performance
May 1, 2025 SMMT -0.98%
In a landscape of rising revenues and increasing operational costs, the company navigates challenges with a focus on innovation and sustainability. Despite a dip in net income and profit declines...
February 5, 2025 TEVA -1.44%
In a year marked by resilience, the company celebrated record revenues of $25 billion, driven by strong ticket sales and operational efficiency. With a focus on North America, it reduced...
January 27, 2025 CUK -2.00%